Ameriprise Financial Inc. boosted its stake in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 419.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,127,694 shares of the biopharmaceutical company’s stock after purchasing an additional 1,717,841 shares during the quarter. Ameriprise Financial Inc. owned 1.30% of Horizon Pharma worth $26,979,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. raised its stake in Horizon Pharma by 82.8% during the 2nd quarter. Russell Investments Group Ltd. now owns 153,668 shares of the biopharmaceutical company’s stock valued at $1,824,000 after purchasing an additional 69,626 shares during the last quarter. Neuberger Berman Group LLC acquired a new position in Horizon Pharma during the 2nd quarter valued at $7,147,000. Bank of New York Mellon Corp raised its stake in Horizon Pharma by 19.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 915,421 shares of the biopharmaceutical company’s stock valued at $10,866,000 after purchasing an additional 150,850 shares during the last quarter. Canada Pension Plan Investment Board raised its stake in shares of Horizon Pharma by 348.9% in the 3rd quarter. Canada Pension Plan Investment Board now owns 101,900 shares of the biopharmaceutical company’s stock valued at $1,292,000 after buying an additional 79,200 shares in the last quarter. Finally, Sei Investments Co. raised its stake in shares of Horizon Pharma by 68.5% in the 3rd quarter. Sei Investments Co. now owns 391,170 shares of the biopharmaceutical company’s stock valued at $4,961,000 after buying an additional 159,002 shares in the last quarter. Hedge funds and other institutional investors own 86.59% of the company’s stock.
Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at $14.48 on Thursday. The company has a quick ratio of 1.52, a current ratio of 1.64 and a debt-to-equity ratio of 1.89. Horizon Pharma PLC has a fifty-two week low of $9.45 and a fifty-two week high of $20.03. The firm has a market cap of $2,304.23, a PE ratio of 10.19, a PEG ratio of 1.19 and a beta of 1.31.
A number of brokerages have recently issued reports on HZNP. Cantor Fitzgerald restated an “overweight” rating and issued a $17.00 price objective (up previously from $13.00) on shares of Horizon Pharma in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of Horizon Pharma from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. BMO Capital Markets restated an “outperform” rating and issued a $18.00 price objective (up previously from $17.00) on shares of Horizon Pharma in a research note on Thursday, August 10th. Goldman Sachs Group began coverage on shares of Horizon Pharma in a research note on Thursday, September 28th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, Jefferies Group restated a “buy” rating and issued a $16.00 price objective on shares of Horizon Pharma in a research note on Thursday, October 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $18.75.
TRADEMARK VIOLATION WARNING: “Horizon Pharma PLC (HZNP) Shares Bought by Ameriprise Financial Inc.” was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2017/12/07/horizon-pharma-plc-hznp-shares-bought-by-ameriprise-financial-inc.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
What are top analysts saying about Horizon Pharma PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Horizon Pharma PLC and related companies.